Dr. Scott Gottlieb is the former commissioner of the Food and Drug Administration and resident fellow at the American Enterprise Institute, where he continues his work on improving public health through entrepreneurship and medical innovation and on expanding regulatory approaches to maintain patient and physician autonomy. 

We talked about regulatory approaches to making prescription drugs more affordable. Learn why price controls, like those which would be implemented in the Democrats’ drug pricing bill HR3, have terrible consequences for the development and innovation of prescription drugs.